Sign in

    Christopher A. Viehbacher

    President and Chief Executive Officer at Biogen Inc
    Since November 14, 2022
    Age
    64 years
    Education
    Earned a Bachelor of Commerce degree from Queen's University in Kingston, Ontario, Canada.
    Tenure
    Joined BIIB as President and Chief Executive Officer in November 2022, serving also as a member of its Board of Directors.

    Also at Biogen Inc

    GGP
    Ginger Gregory, Ph.D.
    Executive Vice President and Chief Human Resources Officer
    MRM
    Michael R. McDonnell
    Executive Vice President and Chief Financial Officer (until February 28, 2025)
    NM
    Nicole Murphy
    Executive Vice President, Pharmaceutical Operations and Technology

    About

    A seasoned executive with a strong international background, he began his career at PricewaterhouseCoopers LLP where he qualified as a chartered accountant and later spent over 20 years at GlaxoSmithKline, holding various roles including the President of its North American pharmaceutical division.

    He further refined his leadership capabilities as the Global CEO of Sanofi from 2008 to 2014 and served as Managing Partner at Gurnet Point Capital from 2015 to 2022, experiences that have provided him with deep insights into both large-scale pharmaceutical operations and innovative biotech ventures.

    At BIIB, he brought his expansive expertise to the role of President and Chief Executive Officer in November 2022, complementing his strategic vision with active contributions on multiple public company boards and academic boards, such as those of Vedanta Biosciences and Northeastern University.

    $BIIB Performance Under Christopher A. Viehbacher

    Past Roles

    OrganizationRoleDate RangeDetails
    Gurnet Point Capital Managing Partner 2015 - 2022Boston-based investment fund role
    Sanofi S.A. Global CEO 2008 - 2014Focused on creating new revenue sources while addressing loss of exclusivity for its portfolio
    GlaxoSmithKline (GSK) Various roles including President of the North American pharmaceutical division Over 20 yearsHeld positions across Germany, Canada, France, and the U.S.
    PricewaterhouseCoopers LLP Early career role / Chartered Accountant N/ABegan his career and qualified as a chartered accountant
    Healthcare Investment Fund Co-founder N/AContributed to the development of innovative companies

    External Roles

    OrganizationRoleDate RangeDetails
    Northeastern University Trustee N/ACurrent position
    Stanford Medical School Member of the Board of Fellows N/ACurrent position

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,600,000 Annual Fixed base salary for the year 2023
    Company Matching Contribution to 401(k) Plan$19,800 Annual Matching contribution to 401(k) as per plan
    Company Contribution to SSP Account$72,983 Annual Contribution to the Supplemental Savings Plan
    Value of Company-Paid Life Insurance Premiums$1,091 Annual Cost of company-paid life insurance premiums

    Performance Compensation

    Data from  FY 2023

    Annual Bonus Plan

    MetricValueAdditional Details
    Target Bonus Opportunity150% of Base Salary Based on achieving company and individual performance goals
    Base Salary for Calculation$1,600,000 Used as the basis for bonus calculation
    Company MultiplierRange: 0% to 150% Actual performance at approximately 99% indicated by company results
    Individual MultiplierRange: 0% to 150% Based on individual performance; actual value here is pegged at 100%
    Cap on Combined Multiplier225% of Target The combined multiplier cannot exceed this limit
    Bonus Award$2,376,000 Final calculated bonus payout for 2023
    Performance Metrics EvaluatedRevenue, EPS, Pipeline, ESG Revenue achieved at 99.5% & EPS at 99.4% of targets ; plus strategic and operational metrics
    Evaluation PeriodCalendar Year 2023 Performance assessed for the 2023 fiscal year

    _No additional performance compensation such as Long-Term Incentive Awards or Performance-Based Restricted Stock Units were applicable in 2023. _